NMR (400 MHz, CD 3 OD): δ 5.13 (s, 1H), 5.09 (s, 1H), 4. 16 -4.11 (m, 1H), 3.91 -3.86 (m, 1H), 3.79 -3.19 (m, 14H) , 2.17 -1.95 (m, 3H), 1.57 -1.51 (m, 13H), 1.51 -1.41 (m, 42H); HR-ESI-MS calculated for C 49 H 89 N 8 O 20 [M+H] + 1109.6188, found 1109.6186
6''-Deoxy-6''-guanidinotobramycin· 6 TFA (2). DCM (3.75 mL) and TIPS (0.2 mL) were added to 6''-deoxy-6''-guanidino-(Boc) 6 kanamycin A (20) (150 mg, 0.12 mmol). TFA (3.75 mL) was added. The yellow solution was stirred for 2.5 hours. Toluene (8 mL) was added and the solvent was removed under reduced pressure. The remaining white solid was dissolved in water and purified by reverse phase HPLC (0 -0.1% ACN in water (0.1% TFA) over 13 min) eluted after 10.2 min, then lyophilized. Product: White powder (117 mg, 0.098 mmol, 79% yield). 1 H-NMR (400 MHz, D 2 O): δ 5.74 (d, J = 3.2 Hz, 1H), 5.10 (d, J = 3.6 Hz, 1H), 4. 05 -3.90 (m, 4H), 3.83 -3.66 (m, 4H), 3.64 -3.47 (m, 6H) , 3.41 (dd, J 1 = 14 Hz, J 2 = 3.6 Hz, 1H), 3.27 (q, J = 7 Hz, 1H), 2.54 (dt, J 1 = 12.8 Hz, J 2 = 4.2 Hz, 1H), 2.29 (dt, J 1 = 12.4 Hz, J 2 = 4.4 Hz, 1H), 2.03 (q, J = 11.6 Hz, 1H), 1.92 (q, J = 12.8 Hz, 1H); 101.42, 94.74, 84.25, 78.17, 74.73, 71.84, 71.10, 68.61, 66.41, 64.91, 55.29, 50.49, 48.94, 48.32, 41.86, 40.32, 29.82, 28.35 (Boc) 4 Amikacin (S1). Water (2.1 mL), DMF (2.5 mL), and TEA (1.3 mL, 12.81 mmol) were added to amikacin sulfate (5) (500 mg, 0.85 mmol). The reaction was heated to 55 °C and di-tert-butyl dicarbonate (1.12 g, 5.12 mmol) dissolved in DMF (8 mL) was added slowly. The pale yellow solution was stirred for 6 hours. The solvent was removed under reduced pressure and the resulting solid was suspended in warm water. The solid was filtered and washed thoroughly with water. The product was dissolved in ACN and the solvent was removed under reduced pressure. Product: White solid (816 mg, 0.83 mmol, 97% yield 6''-Deoxy-6''-amino-(Boc) 4 amikacin (S3). Anhydrous methanol (7.5 mL) was added to 6''-deoxy-6''-triisopropylbenzylsulfonyl-(Boc) 4 amikacin (S2) (480 mg, 0.39 mmol) in a pressure tube. The yellow solution was cooled to 0 °C and anhydrous ammonia was bubbled into the solution for 10 mins. The vessel was capped and heated to 80 °C for 2 days. The vessel was cooled to 0 °C and opened. 6''-Deoxy-6''-guanidinoamikacin· 5 TFA (5). DCM (0.9 mL) and TIPS (40 µL) were added to 6''-deoxy-6''-guanidino-(Boc) 6 amikacin (S4) (43 mg, 0.033 mmol). TFA (0.9 mL) was added. The yellow solution was stirred for 2.5 hours. Toluene (2 mL) was added and the solvent was removed under reduced pressure. The remaining white solid was dissolved in water and purified by reverse phase HPLC (0 -6% ACN in water (0.1% TFA) over 12 min) eluted after 5. 98.60, 97.82, 73.61, 72.72, 71.48, 71.20, 71.03, 70.10, 69.36, 68.57, 66.98, 55.78, 49.46, 48.69, 41.94, 40.81, 37.51, 31.44, 30.81 
TFA, TIPS, DCM.
6''-Deoxy-6''-amino-(Boc) 4 kanamycin A (S7). Synthesis and characterization of precursors S5 and S6 were previously reported.
[S1] Anhydrous methanol (10 mL) was added to 6''-deoxy-6''-triisopropylbenzylsulfonyl-(Boc) 4 kanamycin A (S6) (325 mg, 0.28 mmol) in a pressure tube. The yellow solution was cooled to 0 °C and anhydrous ammonia was bubbled into the solution for 10 mins. The vessel was capped and heated to 80 °C for 2 days. The vessel was cooled to 0 °C and opened. After 5 mins DOWEX ® Monosphere ® 550A ion exchange resin ( -OH form) was added. The reaction was stirred for 12 hours at rt and filtered. The solvent was removed under reduced pressure and the resulting solid was dissolved in DCM and washed with a 2 M sodium bicarbonate solution. The organic layer was dried over sodium sulfate and the solvent was removed under reduced pressure. Product: White solid (227 mg, 0.26 mmol, 91% yield). 6''-Deoxy-6''-guanidino-(Boc) 6 kanamycin A (S8). DCM (3 mL), methanol (0.6 mL), and TEA (65 µL, 0.45 mmol) were added to 6''-deoxy-6''-amino-(Boc) 4 kanamycin A (S7) (200 mg, 0.23 mmol). 1,3-Diboc-2-(trifluoromethylsulfonyl)guanidine (885 mg, 2.26 mmol) was added. The light yellow solution was stirred for 3 days. The solvent was removed under reduced pressure. The product was isolated by flash chromatography (0 -7% methanol in DCM). Product: White solid (202 mg, 0.18 mmol, 79% yield). 1 H-NMR (400 MHz, CD 3 OD): δ 5.12 (s, 1H), 5.06 (s, 1H), 3.88 -3.82 (m, 1H), 3.77 -3.65 (m, 3H), 3.63 -3.30 (m, 12H), 3.13 (q, J = 6.6 Hz, 1H), 2.07 -2.00 (m, 1H), 1.60 -1.38 (m, 16H), 1.30 -1.14 (m, 39H); HR-ESI-MS calculated for C 49 H 88 N 7 O 22 [M+H] + 1126.5977, found 1126.5973
6''-Deoxy-6''-guanidinokanamycin A· 5 TFA (8). DCM (1.5 mL) and TIPS (0.1 mL) were added to 6''-deoxy-6''-guanidino-(Boc) 6 kanamycin A (S8) (67 mg, 0.060 mmol). TFA (1.5 mL) was added. The yellow solution was stirred for 2.5 hours. Toluene (3 mL) was added and the solvent was removed under reduced pressure. The remaining white solid was dissolved in water and purified by reverse phase HPLC (0 -7% 101.42, 98.64, 84.25, 80.02, 73.95, 72.54, 71.78, 71.47, 71.17, 69.38, 68.70, 66.85, 55.41, 50.63, 48.63, 42.12, 40.78, 28.25 5''-Deoxy-5''-guanidino-(Boc) 8 neomycin (S12). Synthesis and characterization of precursors S9 -S11 were previously reported. [S2-S4] DCM (2.5 mL), methanol (0.1 mL), and TEA (40 µL, 0.28 mmol) were added to 5''-deoxy-5''-amino-(Boc) 6 neomycin (S11) (226 mg, 0.19 mmol). 1,3-Di-boc-2-(trifluoromethylsulfonyl)guanidine (728 mg, 1.86 mmol) was added. The yellow solution was stirred for 3 days. The solvent was removed under reduced pressure. The product was isolated by flash chromatography (0 -7% methanol in DCM 5''-Deoxy-5''-guanidinoneomycin· 7 TFA (10). DCM (1.26 mL) and TIPS (65 µL) were added to 5''-deoxy-5''-guanidino-(Boc) 8 neomycin (S12) (73 mg, 0.05 mmol). TFA (1.26 mL) was added. The yellow solution was stirred for 3 hours. Toluene (3 mL) was added and the solvent was removed under reduced pressure. The remaining white solid was dissolved in water and purified by reverse phase HPLC (5 -8% ACN in water (0.1% TFA) over 10 min) eluted after 6 min, then lyophilized. Product: White powder (70 mg, 0.05 mmol, 96% yield). 15, 96.17, 94.62, 85.88, 79.63, 77.89, 75.39, 73.86, 72.96, 71.28, 70.76, 70.56, 68.70, 68.24, 68.11, 53.91, 51.46, 50.28, 49.20, 44.63, 41.13, 40.87, 28. 5'',6'-Dideoxy-5'',6'-di(triisopropylbenzylsulfonyl)-(Boc) 5 paromomycin (S14). Synthesis and characterization of precursor S13 was previously reported. [S5] Anhydrous pyridine (22 mL) was added to (Boc) 5 paromomycin (S13) (1.63 g, 1.46 mmol). Triisopropylbenzylsulfonyl chloride (8.84 g, 29.2 mmol) was added. The orange solution was stirred for 2 days. The solvent was removed under reduced pressure. The product was isolated by flash chromatography (0 -4% methanol in DCM 5'',6'-Dideoxy-5'',6'-diamino-(Boc) 5 paromomycin (S15). Anhydrous methanol (15.8 mL) was added to 5'',6'-dideoxy-5'',6'-di(triisopropylbenzylsulfonyl)-(Boc) 5 paromomycin (S14) (1.31 g, 0.83 mmol) in a pressure tube. The pale yellow solution was cooled to 0 °C and anhydrous ammonia was bubbled into the solution for 10 mins. The vessel was capped and heated to 80 °C for 2 days. The vessel was cooled to 0 °C and opened. After 5 mins DOWEX ® Monosphere ® 550A ion exchange resin ( -OH form) was added. The reaction was stirred for 12 hours at rt and filtered. The solvent was removed under reduced pressure and the resulting solid was dissolved in DCM and washed with a 2 M sodium bicarbonate solution. The organic layer was dried over sodium sulfate and the solvent was removed under reduced pressure. Product: Light yellow solid (811 mg, 0.73 mmol, 88% yield). 5'',6'-Dideoxy-5'',6'-diguanidino-(Boc) 9 paromomycin (S16). DCM (9.2 mL), methanol (0.5 mL), and TEA (0.29 mL, 2.05 mmol) were added to 5'',6'-dideoxy-5'',6'-diamino-(Boc) 5 paromomycin (S15) (761 mg, 0.68 mmol). 1,3-Di-boc-2-(trifluoromethylsulfonyl)guanidine (1.80 g, 4.78 mmol) was added. The yellow solution was stirred for 3 days. The solvent was removed under reduced pressure. The product was isolated by flash chromatography (0 -7% methanol in DCM 5'',6'-Dideoxy-5'',6'-diguanidinoparomomycin· 7 TFA (14). DCM (3 mL) and TIPS (0.15 mL) were added to 5'',6'-dideoxy-5'',6'-diguanidino-(Boc) 9 paromomycin (S16) (183 mg, 0.12 mmol). TFA (3 mL) was added. The yellow solution was stirred for 3 hours. Toluene (6 mL) was added and the solvent was removed under reduced pressure. The remaining white solid was dissolved in water and purified by reverse phase HPLC (0 -0.1% ACN in water (0.1% TFA) over 10 min) eluted after 8.5 min, then lyophilized. Product: White powder (149 mg, 0.10 mmol, 82% yield). (Boc) 5 Apramycin (21). Water (1.9 mL), DMF (2.1 mL), and TEA (1.2 mL, 11.76 mmol) were added to apramycin sulfate (15) (500 mg, 0.78 mmol). The reaction was heated to 55 °C and di-tert-butyl dicarbonate (1.03 g, 4.70 mmol) dissolved in DMF (7.5 mL) was added slowly. 6''-Deoxy-6''-triisopropylbenzylsulfonyl-(Boc) 5 apramycin (22). Anhydrous pyridine (4.6 mL) was added to (Boc) 5 apramycin (21) (420 mg, 0.40 mmol). Triisopropylbenzylsulfonyl chloride (1.22 g, 4.03 mmol) was added. The orange solution was stirred for 36 hours. The solvent was removed under reduced pressure. The product was isolated by flash chromatography (0 -5% methanol in DCM). Product: White solid (160 mg, 0.12 mmol, 31% yield). 6''-Deoxy-6''-amino-(Boc) 5 apramycin (23). DMF (2.5 mL) was added to 6''-deoxy-6''-triisopropylbenzylsulfonyl-(Boc) 5 apramycin (22) (160 mg, 0.12 mmol). Sodium azide (64 mg, 0.98 mmol) was added. The yellow solution was heated to 55 °C and stirred for 2 days. The solvent was removed under reduced pressure and the resulting solid was dissolved in DCM and washed with water. The organic layers were dried with sodium sulfate and the solvent was removed under reduced pressure. Anhydrous methanol (1.1 mL) and acetic acid (10 µL) were added to the resulting white solid. The solution was degassed by bubbling through argon. Pd/C (10%, 14 mg, 0.013 mmol) was added and the reaction was stirred under atmospheric H 2 overnight. The solution was filtered through celite and the solvent was removed under reduced pressure. The product was isolated by flash chromatography (10% methanol, 1% TEA in DCM). Product: White solid (102 mg, 0.098 mmol, 80% yield). 6''-Deoxy-6''-guanidino-(Boc) 7 apramycin (24). DCM (0.7 mL), methanol (0.14 mL), and TEA (15 µL, 0.11 mmol) were added to 6''-deoxy-6''-amino-(Boc) 5 apramycin (23) (55 mg, 0.05 mmol). 1,3-Di-boc-2-(trifluoromethylsulfonyl)guanidine (207 mg, 0.53 mmol) was added. The light yellow solution was stirred for 3 days. The solvent was removed under reduced pressure. The product was isolated by flash chromatography (0 -6% methanol in DCM). Product: White solid (50 mg, 0.04 mmol, 74% yield). 6''-Deoxy-6''-guanidinoapramycin· 6 TFA (16). DCM (1 mL) and TIPS (50 µL) were added to 6''-deoxy-6''-guanidino-(Boc) 6 kanamycin A (24) (50 mg, 0.039 mmol). TFA (1 mL) was added. The yellow solution was stirred for 2 hours. Toluene (2 mL) was added and the solvent was removed under reduced pressure. The remaining white solid was dissolved in water and purified by reverse phase HPLC (0 -0.1% ACN in water (0.1% TFA) over 12 min) eluted after 9.6 min, then lyophilized. Product: White powder (38 mg, 0.030 mmol, 78% yield). 96.23, 94.88, 93.60, 78.83, 75.77, 73.20, 70.63, 70.38, 69.45, 68.71, 66.83, 63.41, 60.15, 57.99, 52.50, 50.32, 49.09, 48.60, 30.73, 28.98, 27.44 Amine to Guanidinium Conversions 6'-guanidinoneamine (12) was previously synthesized. [S6] Scheme S7: 6'-Guanidinotobramycin synthesis. 101.32, 95.54, 84.44, 78.88, 74.62, 73.57, 73.42, 68.60, 65.88, 63.90, 60.39, 55.45, 50.15, 48.96, 48.52, 41.83, 30.09, 28.40; 6', γ-Diguanidinoamikacin· 4 TFA (6). Water (15.5 mL), methanol (20.1 mL), and TEA (0.23 mL, 1.72 mmol) were added to amikacin sulfate (4) (300 mg, 0.34 mmol). 1,3-Di-boc-2-(trifluoromethylsulfonyl)guanidine (245 mg, 0.62 mmol) was added. The light yellow solution was stirred for 5 days. The solvent was removed under reduced pressure. DCM (8.6 mL) and TIPS (0.5 mL) were added to the remaining solid. TFA (8.6 mL) was added. The pale yellow solution was stirred for 2 hours. Toluene (17 mL) was added and the solvent was removed under reduced pressure. 98.01, 97.80, 80.54, 79.89, 73.62, 72.84, 71.94, 71.56, 70.27, 69.58, 68.65, 65.96, 65.55, 60.10, 55.86, 49.35, 48.84, 42.40, 38.38, 33.03, 30.85 ; HR-ESI-MS calculated for C 24 H 48 N 9 O 13 [M+H] + 670.3366, found 670.3365
S.2 -2-D NMR
Tobramycin (1), 6'-guanidinotobramycin (3), amikacin (4), and 6',γ-diguanidinoamikacin (6) were fully assigned by COSY and chemical shifts were compared to verify that only amines at primary sites were converted to guanidinium groups. It should be noted that all 2-D NMR spectra were performed on desalted aminoglycosides, unlike the 1-D 1 H NMR spectra, which were taken on TFA salts.
Tobramycin (1):
6'-Guanidinotobramycin (3): 
S.3 -A-Site Binding Assay Aminoglycoside Titrations
All titrations were performed with working solutions of 1 µM Dy-547 labeled A-site in 20 mM cacodylate buffer (pH = 7.0, 100 mM NaCl, 0.5 mM EDTA). The solutions were heated to 75 °C for 5 min, cooled to room temperature over 2 h, cooled to 0 °C for 30 min, then allowed to warm back to room temperature. Kanamycin-courmarin or neomycin-coumarin was added, to give a working concentration of 0.53 µM, just prior to aminoglycoside titrations. Steady state fluorescence experiments were carried out at ambient temperature (20 °C). Excitation and emission slit widths were 9 nm for kanamycin-coumarin experiments and 7 nm for neomycin-coumarin. The system was excited at 400 nm and changes in Dy-547 emission were monitored at 561 nm. Errors were generated from three sets of measurements. IC 50 values were calculated using OriginPro 8.5 software by fitting a dose response curve (eq 1) to the fractional fluorescence saturation (F s ) plotted against the log of antibiotic (A) concentration. (1) F s is the fluorescence intensity at each titration point. F 0 and F ∞ are the fluorescence intensity in the absence of aminoglycoside or at saturation, respectively, and n is the Hill coefficient or degree of cooperativity associated with binding. Figure S1 : Kanamycin-Coumarin displacement curves. A = Tobramycin (1), B = 6''-Deoxy-6''-guanidinotobramycin (2), C = 6'-Guanidinotobramycin (3), D = Amikacin (4), E = 6''-Deoxy-6''-guanidinoamikacin (5), F = 6',γ-Diguanidinoamikacin (6), G = Kanamycin A (7), H = 6''-Deoxy-6''-guanidinokanamycin A (8), I = Neamine (11), J = 6'-guanidinoneamine (12), K = Apramycin (15), L = 6''-Deoxy-6''-guanidinoapramycin (16) Figure S2 : Neomycin-Coumarin displacement curves. A = Neomycin (9), B = 5''-Deoxy-5''-guanidinoneomycin (10), C = Paromomycin (13), D = 5'',6'-Dideoxy-5'',6'-diguanidinoparomomycin (14)
Binding Curves

S.4 -Parent Aminoglycoside Crystal Structures
All crystal structure representations were made using PyMOL Molecular Graphics Systems, Version 1.4.1, Schrödinger, LLC. All structures were adapted from PDB files: Tobramycin (1LC4), amikacin (2GSQ), kanamycin A (2E5I), neomycin (2ET4), neamine (2ET8), paromomycin (1J7T), apramycin (1YRJ). 
